Moreover, the SRC family kinase activity is observed in hormone-refractory PRAD [127], suggesting that medications targeting the SRC family, such as A.770041, AZD.0530, and WH.4.023, could be effective in PRAD treatment. Here, SRC is linked to prostate adenocarcinoma.